Mutation detection in congenital long QT syndrome

cardiac channel gene screen using PCR, dHPLC, and direct DNA sequencing.

David J. Tester, Melissa L. Will, Michael John Ackerman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Within the field of molecular cardiac electrophysiology, the previous decade of research elucidated the fundamental genetic substrate underlying many arrhythmogenic disorders such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Andersen-Tawil syndrome, Brugada Syndrome, and Timothy syndrome. In addition, the genetic basis for cardiomyopathic processes vulnerable to sudden arrhythmic death-hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy-are understood now in greater detail. The majority of congenital LQTS is understood as a primary cardiac channelopathy that often but not always provides evidence of its presence via a prolonged QT interval on the 12-lead surface electrocardiogram. To date, more than 300 mutations have been identified in five genes encoding key ion channel sub units involved in the orchestration of the heart's action potential. LQTS genetic testing has been performed in research laboratories over the past decade, relying on the techniques of PCR, an intermediate mutation analysis platform such as single-stranded conformation polymorphism (SSCP) or denaturing high-performance liquid chromatography (dHPLC), and subsequent direct DNA sequencing to elucidate the genetic underpinnings of this disorder. Presently, LQTS genetic testing is a clinically available molecular diagnostic test that provides comprehensive open reading frame/splice site mutational analysis via high-throughput DNA sequencing. This chapter will focus on LQTS genetic testing employing the techniques of genomic DNA isolation from peripheral blood, exon-specific PCR amplification, dHPLC hetero-duplex analysis, and direct DNA sequencing.

Original languageEnglish (US)
Pages (from-to)181-207
Number of pages27
JournalMethods in molecular medicine
Volume128
StatePublished - 2006

Fingerprint

Long QT Syndrome
DNA Sequence Analysis
High Pressure Liquid Chromatography
Genetic Testing
Polymerase Chain Reaction
Mutation
Genes
Andersen Syndrome
Cardiac Electrophysiology
Channelopathies
Arrhythmogenic Right Ventricular Dysplasia
Brugada Syndrome
High-Throughput Nucleotide Sequencing
Inborn Genetic Diseases
Molecular Pathology
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Sudden Death
Ion Channels
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mutation detection in congenital long QT syndrome : cardiac channel gene screen using PCR, dHPLC, and direct DNA sequencing. / Tester, David J.; Will, Melissa L.; Ackerman, Michael John.

In: Methods in molecular medicine, Vol. 128, 2006, p. 181-207.

Research output: Contribution to journalArticle

@article{c6ed1b9ff1464dc59d11aeb1dad66780,
title = "Mutation detection in congenital long QT syndrome: cardiac channel gene screen using PCR, dHPLC, and direct DNA sequencing.",
abstract = "Within the field of molecular cardiac electrophysiology, the previous decade of research elucidated the fundamental genetic substrate underlying many arrhythmogenic disorders such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Andersen-Tawil syndrome, Brugada Syndrome, and Timothy syndrome. In addition, the genetic basis for cardiomyopathic processes vulnerable to sudden arrhythmic death-hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy-are understood now in greater detail. The majority of congenital LQTS is understood as a primary cardiac channelopathy that often but not always provides evidence of its presence via a prolonged QT interval on the 12-lead surface electrocardiogram. To date, more than 300 mutations have been identified in five genes encoding key ion channel sub units involved in the orchestration of the heart's action potential. LQTS genetic testing has been performed in research laboratories over the past decade, relying on the techniques of PCR, an intermediate mutation analysis platform such as single-stranded conformation polymorphism (SSCP) or denaturing high-performance liquid chromatography (dHPLC), and subsequent direct DNA sequencing to elucidate the genetic underpinnings of this disorder. Presently, LQTS genetic testing is a clinically available molecular diagnostic test that provides comprehensive open reading frame/splice site mutational analysis via high-throughput DNA sequencing. This chapter will focus on LQTS genetic testing employing the techniques of genomic DNA isolation from peripheral blood, exon-specific PCR amplification, dHPLC hetero-duplex analysis, and direct DNA sequencing.",
author = "Tester, {David J.} and Will, {Melissa L.} and Ackerman, {Michael John}",
year = "2006",
language = "English (US)",
volume = "128",
pages = "181--207",
journal = "Methods in molecular medicine",
issn = "1543-1894",
publisher = "Humana Press",

}

TY - JOUR

T1 - Mutation detection in congenital long QT syndrome

T2 - cardiac channel gene screen using PCR, dHPLC, and direct DNA sequencing.

AU - Tester, David J.

AU - Will, Melissa L.

AU - Ackerman, Michael John

PY - 2006

Y1 - 2006

N2 - Within the field of molecular cardiac electrophysiology, the previous decade of research elucidated the fundamental genetic substrate underlying many arrhythmogenic disorders such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Andersen-Tawil syndrome, Brugada Syndrome, and Timothy syndrome. In addition, the genetic basis for cardiomyopathic processes vulnerable to sudden arrhythmic death-hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy-are understood now in greater detail. The majority of congenital LQTS is understood as a primary cardiac channelopathy that often but not always provides evidence of its presence via a prolonged QT interval on the 12-lead surface electrocardiogram. To date, more than 300 mutations have been identified in five genes encoding key ion channel sub units involved in the orchestration of the heart's action potential. LQTS genetic testing has been performed in research laboratories over the past decade, relying on the techniques of PCR, an intermediate mutation analysis platform such as single-stranded conformation polymorphism (SSCP) or denaturing high-performance liquid chromatography (dHPLC), and subsequent direct DNA sequencing to elucidate the genetic underpinnings of this disorder. Presently, LQTS genetic testing is a clinically available molecular diagnostic test that provides comprehensive open reading frame/splice site mutational analysis via high-throughput DNA sequencing. This chapter will focus on LQTS genetic testing employing the techniques of genomic DNA isolation from peripheral blood, exon-specific PCR amplification, dHPLC hetero-duplex analysis, and direct DNA sequencing.

AB - Within the field of molecular cardiac electrophysiology, the previous decade of research elucidated the fundamental genetic substrate underlying many arrhythmogenic disorders such as long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Andersen-Tawil syndrome, Brugada Syndrome, and Timothy syndrome. In addition, the genetic basis for cardiomyopathic processes vulnerable to sudden arrhythmic death-hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy-are understood now in greater detail. The majority of congenital LQTS is understood as a primary cardiac channelopathy that often but not always provides evidence of its presence via a prolonged QT interval on the 12-lead surface electrocardiogram. To date, more than 300 mutations have been identified in five genes encoding key ion channel sub units involved in the orchestration of the heart's action potential. LQTS genetic testing has been performed in research laboratories over the past decade, relying on the techniques of PCR, an intermediate mutation analysis platform such as single-stranded conformation polymorphism (SSCP) or denaturing high-performance liquid chromatography (dHPLC), and subsequent direct DNA sequencing to elucidate the genetic underpinnings of this disorder. Presently, LQTS genetic testing is a clinically available molecular diagnostic test that provides comprehensive open reading frame/splice site mutational analysis via high-throughput DNA sequencing. This chapter will focus on LQTS genetic testing employing the techniques of genomic DNA isolation from peripheral blood, exon-specific PCR amplification, dHPLC hetero-duplex analysis, and direct DNA sequencing.

UR - http://www.scopus.com/inward/record.url?scp=34547847188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547847188&partnerID=8YFLogxK

M3 - Article

VL - 128

SP - 181

EP - 207

JO - Methods in molecular medicine

JF - Methods in molecular medicine

SN - 1543-1894

ER -